5 stories mentioning KRX:128940Updated 8d ago
Every FINWIRES story that references KRX:128940, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Hanmi Pharmaceutical (KRX:128940) has an average rating of buy and mean price target of 658,666.70 won, according to analysts polled by FactSet.
Hanmi Pharm (KRX:128940) signed an exclusive licensing agreement with Switzerland-based Roche Group member Genentech to develop, manufacture, and commercialize the former's obesity drug, the South Korean firm said in a Monday release.The drug HM17321 (urocortin-2) is a novel metabolic treatment candidate for treating obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, the release said.Under the deal, Hanmi will receive an upfront payment of $190 million, with the total deal valued at $2.3 billion. In addition, the South Korean firm will be eligible to receive tiered royalties on future product sales after commercialization of the drug, it said.Shares of Hanmi Pharm jumped 30% at market close.
Hanmi Pharm. (KRX:128940) posted a 115% year-over-year surge in attributable net income for the second quarter to 83.3 billion won from 38.7 billion won.Sales surged 29% to 467.2 billion won for the three months ended June 30 from 361.3 billion won, based on a bourse filing on Tuesday.
Hanmi Pharm (KRX:128940) granted Eli Lilly worldwide exclusive rights to develop, produce, and market the South Korean drug company's sonefpeglutide biologic drug candidate, according to a Monday news release in Seoul.The rights do not cover Korea, according to Hanmi.Hanmi is set to receive a $75 million upfront payment from the U.S. drug company and an additional $1.19 billion in milestone payments from clinical development, regulatory approval, and commercialization.The South Korean drug company will also be eligible for royalties following the launch.Sonefpeglutide is a long-acting glucagon-like peptide 2 or GLP-2 that helps with intestinal growth. GLP-2 obtained approval for short bowel syndrome.Shares rose 6% during afternoon trading on Monday.
Hanmi Pharm (KRX:128940) signed a technology licensing agreement for Sonefpeglutide (HM15912), a short bowel syndrome drug, with Eli Lilly and Co., according to a Monday filing with the Korea Exchange.The technology licensing agreement is worth up to $1.26 billion, including a $75 million upfront payment and up to $1.185 billion in development, regulatory, and commercial milestones, along with royalties based on future sales, the filing said.Shares of Hanmi Pharm rose more than 7% in recent trade.
